Tectonic Advisors LLC Has $469,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tectonic Advisors LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,439 shares of the medical equipment provider’s stock after buying an additional 792 shares during the quarter. Tectonic Advisors LLC’s holdings in Zimmer Biomet were worth $469,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC grew its stake in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet during the 3rd quarter valued at about $28,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. R Squared Ltd acquired a new position in Zimmer Biomet in the 4th quarter valued at $63,000. Finally, Mather Group LLC. raised its holdings in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock worth $70,000 after acquiring an additional 332 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several research analyst reports. Stifel Nicolaus raised their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Royal Bank of Canada raised their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Truist Financial upped their price target on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Raymond James reduced their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $102.84 on Friday. The stock has a market capitalization of $20.47 billion, a P/E ratio of 19.55, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90. The business has a 50-day moving average price of $107.75 and a two-hundred day moving average price of $108.20.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same period in the previous year, the firm earned $2.20 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.93%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.